On August 3, 2023, Amber Bio, a biotechnology company pioneering multi-kilobase gene editing platforms to reach previously undruggable diseases, announced $26 million in seed funding co-led by Playground Global and Andreessen Horowitz Bio + Health with participation from Eli Lilly, RDF (Retinal Degeneration Fund), Hummingbird Ventures, and Pillar VC. Wilson Sonsini Goodrich & Rosati advised Amber Bio on the transaction.

The funding will be used to advance a first-of-its-kind RNA editing platform which enables multi-kilobase edits, allowing a single drug to treat diseases with high allelic diversity. Amber Bio is developing its own genetic medicine programs in-house.

The Wilson Sonsini team that advised Amber Bio on the transaction included Mark Solakian, Rich Evans, and Aaron Gordon.

For more information, please see Amber Bio's news release. Additional coverage can be found on Forbes and BioWorld.